The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer/Onyx; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Millennium
Research Funding - Advantagene (Inst); Ariad (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst)
 
Scott N. Gettinger
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen
Research Funding - ARIAD (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Pfizer (Inst)
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genoptix; Heat Biologics; Pfizer; Seagen
Speakers' Bureau - Novartis; Pfizer; Roche/Genentech
Research Funding - ARIAD; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Heat Biologics; Johnson & Johnson; Lilly; MedImmune; Merck; Mirati Therapeutics; NanoCarrier; Novartis; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Clovis Oncology; Pfizer; Roche/Genentech; Seagen
 
Ravi Salgia
No Relationships to Disclose
 
Kathryn A. Gold
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Pfizer
Research Funding - ARIAD; AstraZeneca; Bristol-Myers Squibb; Puma Biotechnology; Roche/Genentech
 
Rafael Rosell
No Relationships to Disclose
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; Genentech; Ignyta; Novartis; Pfizer; Roche
 
Glen J. Weiss
Employment - Cancer Treament Centers of America
Consulting or Advisory Role - Blend Therapeutics; Paradigm; Pharmatech
Speakers' Bureau - Amgen; Celgene; Medscape; Pfizer; Quintiles
Patents, Royalties, Other Intellectual Property - US Patent #8,911,940 issued 2014 (Inst)
Travel, Accommodations, Expenses - Cambridge Healthtech Institute; Pharmatech
 
David J. Dorer
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Victor M. Rivera
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Frank G. Haluska
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD